Tendinopathy Market

• The Tendinopathy market size in the 7MM is expected to grow with a ignificant CAGR druing the study period (2020-2034).
• The Tendinopathy treatment involves different modalities that are usually, but not always, used in conjunction with exercise. Tendinopathy treatment involves pharmacological therapies, physical therapies, and therapeutic exercise.
• Compared to scaffolds and growth factors, there is a paucity of clinical studies using stem cells for augmentation of tendon repair or for treating tendinopathy.
• Platelet-rich plasma (PRP) is a well-known therapy for the treatment of tendinopathy. It involves taking a blood sample and spinning the blood to separate the platelets and other healing factors. The solution is then injected into the area of chronic tendon irritation.
• There is considerable potential for the development of new drugs to treat tendinopathy, with NSAIDs and corticosteroids being the primary options for tendonitis. However, in recent years, the Tendinopathy drugs market has seen a proliferation of nutraceutical products that appear to support the healing of tendon injuries and may also serve as preventive measures.
• The company is expected to release data of COSENTYX (secukinumab) from its Phase III trial (NCT05722522) by 2025 for rotator cuff tendinopathy.
• Extracorporeal shock wave therapy (ESWT) is a non-invasive treatment that involves the delivery of shock waves to injured soft tissue to reduce pain and promote healing. It uses high-energy pressure waves and has been used as a treatment for tendinopathy and soft tissue disorders of the shoulder, elbow, hip, knee, and ankle.

Request for unlocking the CAGR of the "Tendinopathy Drugs Market"

DelveInsight’s "Tendinopathy Market Insights, Epidemiology, and Market Forecast – 2034" report delivers an in-depth understanding of Tendinopathy, historical and forecasted epidemiology as well as Tendinopathy market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

The Tendinopathy Treatment Market Report provides current treatment practices, emerging drugs, Tendinopathy market share of individual therapies, and current and forecasted Tendinopathy market size from 2020 to 2034, segmented by seven major markets. The report also covers current Tendinopathy treatment market practices/algorithms and Tendinopathy unmet needs to curate the best of the opportunities and assess the underlying potential of the Tendinopathy drugs market.

Tendinopathy Treatment Market

Tendinopathy Overview

Tendinopathy represents a complex condition characterized by pain and dysfunction within tendons, the fibrous tissues that connect muscles to bones. At its core, tendinopathy manifests as a compromised healing response within the tendon structure. This failure of healing is marked by several key features, including the disorganized growth of tenocytes (the cells responsible for maintaining tendon structure), abnormalities within these cells at the molecular level, as well as the disruption of collagen fibers, which are essential for tendon strength and elasticity.

Consequently, there is an accumulation of non-collagenous matrix substances within the tendon. The term tendinopathy serves as a broad label encompassing various clinical presentations resulting from overuse or repetitive strain on tendons. Symptoms commonly associated with tendinopathy include pain, diminished function, and a reduced capacity for exercise due to the compromised integrity of the affected tendon. Overall, tendinopathy signifies a complex interplay of structural and functional changes within tendons, often precipitated by repetitive stress, and it necessitates a multifaceted approach to management and treatment. 

Tendinopathy Diagnosis

Ultrasound and MRI can be used in the diagnosis of tendinopathy. Imaging should be done with care and should be matched with a patient's clinical presentation. Tendons can be viewed successfully on ultrasound, and this method of imaging is significantly cheaper than MRI. MRI results should also be interpreted with care. An MRI provides a very detailed view and can show pathology that has no relation to the patient's symptoms. Imaging results should, therefore, be interpreted with caution. 

Further details related to diagnosis will be provided in the report…

Tendinopathy Treatment

Tendinopathy treatment options for encompass a range of strategies aimed at addressing both the underlying pathology and symptom management. These include targeted stretching and strengthening exercises tailored to the specific tendon affected, which help improve flexibility and support tendon function. In cases where excess body weight exacerbates the condition, weight loss guidance may be recommended to alleviate stress on the affected tendons.

Additionally, techniques such as bracing can help unload the tendon, providing relief and support during daily activities or exercise. For individuals experiencing inflammation-related pain, corticosteroid injections may be administered to reduce swelling and discomfort. In instances where tendinopathy persists despite conservative measures, surgical intervention might be considered to address severe structural issues. Alongside these conventional treatments, some individuals find relief from tendinopathy symptoms through the application of pain relief oils.

These oils, often containing natural ingredients with anti-inflammatory and analgesic properties, can offer additional comfort and support alongside conventional therapies, contributing to a holistic approach to managing tendinopathy and promoting improved quality of life. 

Tendinopathy Epidemiology

The Tendinopathy epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by the total incident cases of Tendinopathy, gender-specific incident cases of Tendinopathy, type-specific incident cases of Tendinopathy, region-specific cases of Tendinopathy, and total treated cases of Tendinopathy in the 7MM covering the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan from 2020 to 2034. 

• The Incident cases of Tendinopathy are on the rise, and it is estimated that the United States accounted for more than ~12,000,000 cases in 2023.
• Among gender-specific tendinopathy incident cases, males are the primary contributors compared to females in the United States.
• According to estimates, tendinitis and tendinosis are the primary types of tendinopathy, with tendinosis accounting for the highest number of cases in 2023.
• As per the estimates, in the United States, the treated cases of tendinopathy were ~6,000,000 cases in 2023 which is expected to increase during the forecast period.

Unlock comprehensive insights! Click Here to Purchase the Full Epidemiology Report @ Tendinopathy Prevalence

Tendinopathy Drugs Market Chapters

The drug chapter segment of the Tendinopathy market forecast report encloses a detailed analysis of the late-stage (Phase III) and mid-stage (Phase II/III and Phase II) Tendinopathy pipeline drugs. The current key Tendinopathy companies include Causeway Therapeutics (CWT-001), Novartis (Secukinumab) and others. The drug chapter also helps understand the Tendinopathy clinical trials details, pharmacological action, agreements and collaborations, approval, and patent details, and the latest Tendinopathy news and press releases.

Tendinopathy Emerging Drugs

• CWT-001: Causeway Therapeutics

TenoMiR(CWT-001), is a microRNA replacement therapy that directly targets critical disease pathways restoring tendons to normal structure and function. We have shown that a single local injection of TenoMiR improves tendon healing in pre-clinical models. TenoMiR is unique in directly targeting the critical collagen production changes associated with tendinopathy. Unlike other therapies, TenoMiR has a well-defined mode of action that is supported by a wealth of scientific data. Moreover, treatment with TenoMiR does not require invasive biopsies and can be delivered at the point of initial diagnosis, initiating recovery at the very earliest time. 

• COSENTYX (Secukinumab): Novartis

COSENTYX is a fully human biologic that specifically targets and blocks interleukin-17A (IL-17A), an important cytokine involved in the inflammation of psoriatic arthritis (PsA), moderate to severe plaque psoriasis, ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA). COSENTYX is a proven medicine and has been studied clinically for more than 14 years. Currently, the drug is being investigated in Phase III for the rotator cuff tendinopathy. The company is expected to release data from its Phase III trial (NCT05722522) by 2025.

For More Insights of the Report @ COSENTYX Market

Tendinopathy Market Outlook

The tendinopathy treatment market landscape continues to evolve, and several companies are furiously working toward the development of new treatments. Approximately 40-50% of patients undergo physiotherapeutic management. Indeed, the management of tendinopathies with the aid of oral supplementation is a relatively new approach. Oral supplements such as glucosamine and chondroitin sulfate, vitamin C, hydrolyzed type 1 collagen, curcumin, boswellic acid, and methylsulfonylmethane have a potential role in tendon healing.

A specific evaluation of each substance is difficult, also because most of the time combinations of these elements are used, and “multivitamin” combinations are adopted in the athletic and general population. Both the oral and topical delivery of NSAIDs are effective as short-term analgesics for this painful condition. Corticosteroids may be injected around a tendon to relieve tendinitis; injections of cortisone – naturally occurring corticosteroids – reduce inflammation and can help ease the pain. Platelet-rich plasma (PRP) is a well-known therapy for the treatment of tendinopathy.

The tendinopathy pipeline possesses potential drugs as monotherapies as well as combination therapies whereas nutraceuticals emerge as candidates to reduce symptoms attributed to tendinopathies, prevent tendon rupture, and improve recovery from trauma or surgery.

Key Findings

• Among the 7MM, the United States accounted for the largest Tendinopathy market size in 2023. These numbers are expected to increase during the forecast period (2024-2034) owing to increasing advancements in the field of tendinopathy therapeutics. Various organizations and research institutes are undertaking research activities to discover successful tendinopathy treatments as well.
• Gene therapy is a promising method for facilitating the trafficking of growth factors to the injured site, potentially allowing sustained temporal delivery. In addition, novel mini-invasive procedures that target underlying pathology, such as abnormal neoinnervation, are being developed and are initially promising.

Tendinopathy Drugs Uptake

This section focuses on the uptake rate of potential Tendinopathy drugs expected to be launched in the market during 2024–2034. The Tendinopathy treatment market landscape has experienced a transformation with the uptake of novel drugs. These innovative therapies are redefining standards of care. Furthermore, the increased uptake of these transformative drugs is a testament to the unwavering dedication of oncologists, professionals, and the entire healthcare community in their tireless pursuit of advancing healthcare. This momentous shift in treatment paradigms is a testament to the power of research, collaboration, and human resilience.

Tendinopathy Pipeline Development Activities

The Tendinopathy pipeline segment provides insights into Tendinopathy clinical trails within Phase III, Phase II/III, and Phase II. It also analyzes key Tendinopathy companies involved in developing targeted therapeutics. Tendinopathy companies like Causeway Therapeutics, Novartis, and others actively engage in late and mid-stage research and development efforts for Tendinopathy. The Tendinopathy pipeline possesses potential Tendinopathy pipeline drugs. However, there is a positive outlook for the Tendinopathy therapeutics market, with expectations of growth during the forecast period (2024–2034).

Pipeline Development Activities

The Tendinopathy pipeline segment covers information on collaborations, acquisitions and mergers, licensing, and patent details for Tendinopathy emerging therapy.

Take Your Research to the Next Level! Click Here to Get Access to the Full Pipeline Report @ Tendinopathy Treatment Drugs

KOL Views

To keep up with current Tendinopathy market trends, we take KOLs and SMEs' opinions working in the domain through primary research to fill the data gaps and validate our secondary research. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the Tendinopathy drugs market and the Tendinopathy unmet needs.

Qualitative Analysis

We perform Qualitative and market Intelligence analysis using various approaches, such as SWOT analysis and Analyst views. In the SWOT analysis, strengths, weaknesses, opportunities, and threats in terms of disease diagnosis, patient awareness, patient burden, Tendinopathy competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided. These pointers are based on the Analyst’s discretion and assessment of the patient burden, cost analysis, and existing and evolving Tendinopathy treatment market landscape.

Tendinopathy Therapeutics Market Access and Reimbursement

Referring patients with tendinopathy to orthopedists, primary care doctors, and physical therapists is common practice, for patients with tendinopathy, orthopedists may feel that their options are limited. These patients require frequent monitoring.

The United States drug pricing regime is complex given its multi-payer model. It is currently undergoing significant changes, with recent federal legislation, such as the Prescription Drug Pricing Reform provisions of the Inflation Reduction Act, significantly altering the pricing regime under certain federal programs. 

The US healthcare system includes both private and public health insurance coverage. Whether a drug product is covered, and at what price, is determined by each payer’s coverage, coding, and payment criteria for health insurance plans. The largest government-funded programs are Medicare and Medicaid. Private plans, which cover far more Americans than public plans, have more flexibility to make coverage and reimbursement determinations. 

Detailed market access and reimbursement assessment will be provided in the final report.

Tendinopathy Therapeutics Market Report Scope

• The Tendinopathy market size report covers a segment of key events, an executive summary, and a descriptive overview, explaining its causes, signs, symptoms, pathogenesis, and currently used therapies.
• Comprehensive insight into the epidemiology segments and forecasts, disease progression, and treatment guidelines has been provided.
• Additionally, an all-inclusive account of the Tendinopathy emerging therapies and the elaborative profiles of late-stage and prominent therapies will impact the current Tendinopathy treatment market landscape.
• A detailed review of the Tendinopathy drugs market, historical and forecasted Tendinopathy treatment market size, Tendinopathy drugs market share by therapies, detailed assumptions, and rationale behind our approach is included in the report, covering the 7MM drug outreach.
• The patient-based Tendinopathy market forecasting report provides an edge while developing business strategies by understanding trends through SWOT analysis and expert insights/KOL views, patient journey, and treatment preferences that help shape and drive Tendinopathy drugs market.

Tendinopathy Therapeutics Market Report Insights

• Patient-based Tendinopathy Market Forecasting
• Tendinopathy Therapeutic Approaches
• Tendinopathy Pipeline Drugs Analysis
• Tendinopathy Market Size
• Tendinopathy Market Trends
• Existing and Future Tendinopathy Drugs Market Opportunity 

Tendinopathy Therapeutics Market Report Key Strengths

• 11 Years Tendinopathy Market Forecast
• The 7MM Coverage 
• Tendinopathy Epidemiology Segmentation
• Key Cross Competition 
• Tendinopathy Drugs Uptake
• Key Tendinopathy Market Forecast Assumptions

Tendinopathy Treatment Market Report Assessment

• Current Tendinopathy Treatment Market Practices
• Tendinopathy Unmet Needs
• Tendinopathy Pipeline Product Profiles
• Tendinopathy Drugs Market Attractiveness
• Qualitative Analysis (SWOT and Analyst Views)
• Tendinopathy Market Drivers
• Tendinopathy Market Barriers

FAQs

• What was the Tendinopathy market size, the Tendinopathy market size by therapies, Tendinopathy market share (%) distribution in 2023, and what would it look like by 2034? What are the contributing factors for this growth?
• What can be the future treatment paradigm for Tendinopathy?
• What are the disease risks, burdens, and Tendinopathy unmet needs? What will be the growth opportunities across the 7MM concerning the patient population with Tendinopathy?

• What are the current options for the Tendinopathy treatment? What are the current guidelines for treating Tendinopathy in the 7MM?

• What are the recent novel therapies, targets, mechanisms of action, and technologies being developed to overcome the limitations of existing therapies? 
• What is the patient share in Tendinopathy?

Reasons to Buy Tendinopathy Market Forecast Report

• The Tendinopathy market size report will help develop business strategies by understanding the latest trends and changing treatment dynamics driving Tendinopathy.
• Insights on patient burden/disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• Understand the existing Tendinopathy therapeutics market opportunities in varying geographies and the growth potential over the coming years.
• Identifying strong upcoming players in the Tendinopathy market outlook will help devise strategies to help get ahead of competitors.
• Highlights of access and reimbursement policies of current therapies, barriers to accessibility of expensive off-label therapies, and patient assistance programs.
• To understand Key Opinion Leaders’ perspectives around the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future.
• Detailed insights on the Tendinopathy unmet needs of the existing Tendinopathy drugs market so that the upcoming players can strengthen their development and launch strategy.

Stay Updated with us for Recent Articles

• Tendinopathy Market: Infographics
• Latest DelveInsight Blogs